Abstract
Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are rare neoplasms with heterogeneous clinical behavior and potential long-term survival. In 2006/2007, the European Neuroendocrine Tumors Society introduced an important parameter, grade (based on mitoses and Ki-67 proliferation rate), which became part of the latest 2010-WHO classification. Since this is an important tool in the choice of therapeutic algorithm of patients with NETs, our aim was to audit whether retrospective reclassification is possible and feasible and correlate pathological findings with survival. From the histopathology archive, 338 GEP-NETs (1994–2014) were identified, of which 250 were diagnosed pre-2010 and 80 of these have needed, up till now, classification (morphology and grade—mitotic count/Ki-67). Morphology was well differentiated (WD) in 74 cases while only 6 cases were poorly differentiated (PD). Grade was reclassified: G1—45 cases (56 %); G2—28 cases (35 %); G3—7 cases (9 %). Overall survival (OS) in WD NETs was strikingly better compared to PD neoplasms. Differences in OS between grade were statistically significant (p < 0.0001) and, in particular, grade identified a subgroup of patients with WD lesions but with less favorable clinical behavior (OS at 5 years: G1—89 %; G2—48 %; G3—0 %; G1 vs G2 p = 0.03). Feasibility analysis quantified time for reclassification to be between 45 and 64 min/case. Our series confirms the importance of grade in prognostic stratification and underlines that reclassification is feasible, and may prove worthwhile in patient management, especially in view of the potential long survival of patients with NETs and risk of use of inappropriate therapies.
Similar content being viewed by others
References
B.I. Gustafsson, M. Kidd, I.M. Modlin, Neuroendocrine tumors of the diffuse neuroendocrine system. Curr. Opin. Oncol. 20, 1–12 (2008)
I.M. Modlin, K. Oberg, D.C. Chung, R.T. Jensen, W.W. de Herder, R.V. Thakker, M. Caplin, G. Delle Fave, G.A. Kaltsas, E.P. Krenning, S.F. Moss, O. Nilsson, G. Rindi, R. Salazar, P. Ruszniewski, A. Sundin, Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61–72 (2008)
C. Capella, E. Solcia, L.H. Sobin, in Pathology and genetics of tumours of the digestive system, ed. by S.R. Hamilton, L.A. Aaltonen (IARC Press, Lyon, 2000), pp. 77–82
G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard, W.W. de Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth, M. Körner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, all other Frascati Consensus Conference participants, European Neuroendocrine Tumor Society (ENETS), TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449, 395–401 (2006)
G. Rindi, G. Klöppel, A. Couvelard, P. Komminoth, M. Körner, J.M. Lopes, A.M. McNicol, O. Nilsson, A. Perren, A. Scarpa, J.Y. Scoazec, B. Wiedenmann, TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451, 757–762 (2007)
F.T. Bosman, F. Carneiro, R.H. Hruban, N.D. Theise (eds.), WHO classification of tumours of the digestive system (IARC Press, Lyon, 2010), pp. 13–14
L. Sobin, M. Gospodarowicz, C. Wittekind (eds.), UICC/AJCC TNM classification of malignant tumours, 7th edn. (Wiley, New York, 2009)
U.F. Pape, H. Jann, J. Mueller-Nordhorn, A. Bockelbrink, U. Berndt, S.N. Willich, M. Koch, C. Röcken, G. Rindi, B. Wiedenmann, Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113, 256–265 (2008)
H. Jann, S. Roll, A. Couvelard, O. Hentic, M. Pavel, J. Mueller-Nordhorn, M. Koch, C. Roecken, G. Rindi, P. Ruszniewski, B. Wiedenmann, U.F. Pape, Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117, 3332–3341 (2011)
J. Strosberg, A. Nasir, D. Coppola, M. Wick, L. Kvols, Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Human Pathol. 40, 1262–1268 (2009)
J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, Cutsem E. Van, T.J. Hobday, T. Okusaka, J. Capdevila, E.G. de Vries, P. Tomassetti, M.E. Pavel, S. Hoosen, T. Haas, J. Lincy, D. Lebwohl, K. Öberg, RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group, Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 10(364), 514–523 (2011)
F. Grillo, S. Pigozzi, P. Ceriolo, P. Calamaro, R. Fiocca, L. Mastracci, Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections. Histochem. Cell Biol. 144(1), 93–99 (2015)
V. Adsay, Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count. Am. J. Surg. Pathol. 36, 1743–1746 (2012)
M.D. Reid, P. Bagci, N. Ohike, B. Saka, I. Erbarut Seven, N. Dursun, S. Balci, H. Gucer, K.T. Jang, T. Tajiri, O. Basturk, S.Y. Kong, M. Goodman, G. Akkas, V. Adsay, Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies. Modern Pathol. 28, 686–694 (2015)
O. Basturk, Z. Yang, L.H. Tang, R.H. Hruban, V. Adsay, C.M. McCall, A.M. Krasinskas, K.T. Jang, W.L. Frankel, S. Balci, C. Sigel, D.S. Klimstra, The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am. J. Surg. Pathol. 39, 683–690 (2015)
E. Raymond, L. Dahan, J.L. Raoul, Y.J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.S. Chen, D. Hörsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski, Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 10(364), 501–513 (2011)
J.R. Strosberg, R.L. Fine, J. Choi, A. Nasir, D. Coppola, D.T. Chen, J. Helm, L. Kvols, First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 15(117), 268–275 (2011)
K. Öberg, U. Knigge, D. Kwekkeboom, A. Perren, ESMO Guidelines Working Group, Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23 Suppl 7, vii124–vii130 (2012)
Acknowledgments
This work was supported by a University of Genoa Research Grant 2011 awarded to Dr. Grillo.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they do not have any conflicts of interest.
Additional information
Federica Grillo and Manuela Albertelli have contributed equally.
Rights and permissions
About this article
Cite this article
Grillo, F., Albertelli, M., Annunziata, F. et al. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible?. Endocrine 53, 58–62 (2016). https://doi.org/10.1007/s12020-015-0734-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0734-3